

History of Nippon Shinyaku

Nippon Shinyaku, as an R&D-led new drug manufacturer, has continued to create unique new drugs that are needed in every era to help people lead healthier and happier lives. The foundation of the Company's success is its venture spirit and pursuit of originality, which is reflected in the words of its founder, "Making Japanese medicines with Japanese hands."

FY1966

¥5.164 billion

Surpassed ¥5 billion in sales

Founding period–1969

Establishment of a business foundation focused on prescription medicines

- 1919** Founding
- 1940** Launch of Santonin, a vermicide for roundworms manufactured in Japan
- 1961** Start of Functional Foods business
- 1964** Completion of Odawara plant (now Odawara Central Factory)
- 1967** Completion of new premises at the Tokyo Business Office



Odawara plant (now Odawara Central Factory)

FY1992

¥50.534 billion

Surpassed ¥50 billion in sales

1970–1999

Venturing into global business development and drug discovery

- 1971** Launch of Cylocide for solid tumor and acute leukemia
- 1982** Completion of the Main Central Research Lab (now Building No. 1 of Discovery Research Laboratories)
- 1991** Opening of Düsseldorf Office
- 1994** Completion of Building No. 2 of the West Discovery Research Laboratories (now Building No. 2 of Discovery Research Laboratories) at the head office
- 1997** Opening of New York Office (transformed into the local subsidiary NS Pharma Inc. in 1999 and then moved to New Jersey in 2002)



Main Central Research Lab (now Discovery Research Laboratories Building No. 1)

FY2013

¥76.517 billion

Surpassed ¥75 billion in sales

2000–2013

Reinforcement of business foundation to respond to drastic changes in conditions

- 2000** Establishment of Business Philosophy and Management Policy
Start of the 1st Medium-term Management Plan
- 2007** Establishment of Guidelines for Action (Challenge, Speed, Investigation)
- 2011** Launch of Vidaza for myelodysplastic syndromes
- 2011** Opening of the Beijing Representative Office



Discovery Research Laboratories in Tsukuba

FY2017

¥101.448 billion

Surpassed ¥100 billion in sales

FY2022

¥144.175 billion

13th consecutive fiscal year of sales growth

2014–Present

Aiming for global recognition as a manufacturer in the healthcare field

- 2016** Launch of Upravi for pulmonary arterial hypertension (PAH) in the U.S.
- 2020** Launch of Viltepso for Duchenne muscular dystrophy in Japan and the U.S.
- 2021** Establishment of Chinese subsidiaries Beijing Nippon Shinyaku Co., Ltd. and Tianjin Nippon Shinyaku Co., Ltd.
- 2023** Establishment of Innovation Research Partnering, a drug discovery center in the U.S.



NS Pharma

Founding period–1969

In 1940, Nippon Shinyaku succeeded in manufacturing Santonin in Japan, a vermicide for roundworms, which contributed greatly to the reduction of Japan's roundworm infection rate and to the growth of Nippon Shinyaku's business performance. In the 1960s, Nippon Shinyaku diversified its prescription medicines-related activities by creating new drugs through the expansion of its R&D system, including the completion of a new research laboratory, and by introducing products through alliances with overseas companies. It also started its food business at this time. The Company built its business foundation by completing construction of the Odawara plant and building a network of sales bases.

1970–1999

Nippon Shinyaku strengthened its R&D structure by establishing the Main Central Research Lab (now Building No. 1 of Discovery Research Laboratories) and other facilities that comply with GLP standards that ensure the safety and appropriateness of non-clinical studies. In the 1990s, the Company opened offices in Germany and the U.S. and promoted internationalization through business expansion in Japan, the U.S., and Europe. It launched unique new products in the fields of gastroenterology, cardiology, urology, and otorhinolaryngology, and concentrated business resources into the cultivation of mainstay drugs. In the food business, the Company began providing health food ingredients.

2000–2013

In addition to clearly stating its Business Philosophy and Management Policy, Nippon Shinyaku formulated a medium-term management plan to clarify its corporate vision. It invested business resources in focal areas such as urology and hematology, and invested resources in research on nucleic acid drugs at the Discovery Research Laboratories in Tsukuba. By proactively searching for unmet medical needs, the Company has continuously launched products in areas not often handled by major companies, and some of these products have grown to become business drivers.

2014–Present

Under the theme of "pursuit of originality" set forth in the management strategy of the 5th and 6th Five-Year Medium-term Management Plans, Nippon Shinyaku has worked to build a unique foundation by continuously launching new products. These include a small molecule compound and a nucleic acid drug discovered in-house that have achieved global expansion, and have led to the establishment and development of a new business model for the Company, such as starting its own marketing by NS Pharma in the U.S. Nippon Shinyaku will continue to further promote its global business and aim to become a manufacturer that is globally recognized in the healthcare field.